Stop Drug Shortages, Start Domestic Supply Chains
How Phlow is revamping the way medicines are made and distributed.
Phlow’s mission to reliably supply affordable, high-quality, essential medicines through U.S.-based advanced manufacturing processes.
Phlow honored with “Inno on Fire” Award for its impact on U.S.-based pharmaceutical manufacturing of essential medicines.
White House officials called the multi-million dollar contract with Virginia-based Phlow Corp. a potential landmark in returning pharmaceutical manufacture from overseas.
Dr. Eric Edwards, CEO of Phlow Corp., joins “Squawk Alley” to discuss manufacturing essential medicines in the U.S.
A new Richmond-based pharmaceutical manufacturing company has received a $354 million federal contract to help build a strategic, national reserve of essential medications and to make active ingredients for more than a dozen medicines used to treat patients with COVID-19.
Phlow CEO Eric Edwards discusses manufacturing coronavirus treatments and other critical drugs in shortage in partnership with the U.S. government.
Move Strengthens America’s Supply Chain and Supports COVID-19 Response.
The U.S. government signed a $354 million four-year contract with new pharmaceutical company Phlow Corp. to increase American production of medications that may help treat Covid-19 in a bid to avoid potential supply chain shortages, with the potential to extend the contract to $812 million for the next ten years.